Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9. doi: 10.1016/j.bmcl.2009.10.108. Epub 2009 Oct 29.

Pyrazolone based TGFbetaR1 kinase inhibitors.

Author information

1
Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142, USA. kevin.guckian@biogenidec.com

Abstract

Interruption of TGFbeta signaling through inhibition of the TGFbetaR1 kinase domain may prove to have beneficial effect in both fibrotic and oncological diseases. Herein we describe the SAR of a novel series of TGFbetaR1 kinase inhibitors containing a pyrazolone core. Most TGFbetaR1 kinase inhibitors described to date contain a core five-membered ring bearing N as H-bond acceptor. Described herein is a novel strategy to replace the core structure with pyrazolone ring, in which the carbonyl group is designed as an H-bond acceptor to interact with catalytic Lys 232.

PMID:
19914068
DOI:
10.1016/j.bmcl.2009.10.108
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center